Inclusion Criteria:  Age 18 years or older Cancer patients with current symptoms of chemotherapy induced peripheral neuropathy affecting the feet, persisting for at least 3 months after completion of chemotherapy, and not substantially improving in recent weeks. The CIPN must be painful, or severe enough to interfere with function, activities, or participation (generally NCI-CTCAE Grade II) Clinically stable to participate in study assessments and the intervention (at a minimum, able to stand independently from a chair and walk household distances without help from another person) Able to read and speak English, give a voluntary written consent Sufficient cognition to consent, confirmed by recall of key study points Use of pain medications (opioids, anti-convulsants, and antidepressants) must be stable in the two weeks prior to study enrollment, and the participant must agree to avoid significant changes in pain medication regimen during the period of active study participation, and to notify the study team if medications change  Exclusion Criteria:  Diagnosis of diabetes per patient report or based on medication inventory Neuropathy (known or suspected) of any etiology other than chemotherapy (for example, due to diabetes, alcohol, vitamin deficiency, autoimmune disorder, CMT, idiopathic Unsafe/unable to self-apply the focal vibration intervention for any reason (for example, insufficient hand dexterity or cognitive executive function Recent or fluctuating musculoskeletal injury or lesion that would impact physical performance Lower limb deficiency/amputations Pregnant, or planning to get pregnant in the next 6 months. Pre-menopausal females who enroll agree to notify the study team as soon as possible should they become pregnant